José Antonio Nieto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
José Antonio Nieto has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Behnood Bikdeli
Cardiovascular Medicine Division, Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USA
4 shared publicationsManuel Monreal
Chair of Thromboembolic Diseases Universidad Católica San Antonio de Murcia Murcia Spain
4 shared publicationsDamian Mora
Internal Medicine, Hospital Virgen de La Luz, Cuenca, Spain
2 shared publicationsJorge Mateo
Institute of Technology, Universidad de Castilla‐La Mancha Cuenca Spain
2 shared publicationsA. Cuevas Garro
1 shared publicationAgustina Rivas
Department of Pneumonology, Hospital Universitario Araba, Álava, Spain
1 shared publication
Latest Publications
- Open Access
- 22 November 2023
- Published by Elsevier in European Urology Open Science
- Vol. 57, S426
Male slings implantation in an outpatient surgery program
- 22 November 2023
- Published by Elsevier in European Urology Open Science
- Vol. 57, S426
Open AccessMale slings implantation in an outpatient surgery program
- Open Access
- 21 March 2023
- Published by Wiley in British Journal of Haematology
- Vol. 201 (5) , 971-981
Machine learning to predict major bleeding during anticoagulation for venous thromboembolism: possibilities and limitations
Summary: Predictive tools for major bleeding (MB) using machine learning (ML) might be advantageous over traditional methods. We used data from the Registro Informatizado de Enfermedad TromboEmbólica (RIETE) to develop ML algorithms to identify patients with venous thromboembolism (VTE) at increased risk of MB during the first 3 months of anticoagulation. A total of 55 baseline variables were used as predictors. New data prospectively collected from the RIETE were used for further validation. The RIETE and VTE‐BLEED scores were used for comparisons. External validation was performed with the COMMAND‐VTE database. Learning was carried out with data from 49 587 patients, of whom 873 (1.8%) had MB. The best performing ML method was XGBoost. In the prospective validation cohort the sensitivity, specificity, positive predictive value and F1 score were: 33.2%, 93%, 10%, and 15.4% respectively. F1 value for the RIETE and VTE‐BLEED scores were 8.6% and 6.4% respectively. In the external validation cohort the metrics were 10.3%, 87.6%, 3.5% and 5.2% respectively. In that cohort, the F1 value for the RIETE score was 17.3% and for the VTE‐BLEED score 9.75%. The performance of the XGBoost algorithm was better than that from the RIETE and VTE‐BLEED scores only in the prospective validation cohort, but not in the external validation cohort.
- 21 March 2023
- Published by Wiley in British Journal of Haematology
- Vol. 201 (5) , 971-981
Open AccessMachine learning to predict major bleeding during anticoagulation for venous thromboembolism: possibilities and limitations
Summary: Predictive tools for major bleeding (MB) using machine learning (ML) might be advantageous over traditional methods. We used data from the Registro Informatizado de Enfermedad TromboEmbólica (RIETE) to develop ML algorithms to identify patients with venous thromboembolism (VTE) at increased risk of MB during the first 3 months of anticoagulation. A total of 55 baseline variables were used as predictors. New data prospectively collected from the RIETE were used for further validation. The RIETE and VTE‐BLEED scores were used for comparisons. External validation was performed with the COMMAND‐VTE database. Learning was carried out with data from 49 587 patients, of whom 873 (1.8%) had MB. The best performing ML method was XGBoost. In the prospective validation cohort the sensitivity, specificity, positive predictive value and F1 score were: 33.2%, 93%, 10%, and 15.4% respectively. F1 value for the RIETE and VTE‐BLEED scores were 8.6% and 6.4% respectively. In the external validation cohort the metrics were 10.3%, 87.6%, 3.5% and 5.2% respectively. In that cohort, the F1 value for the RIETE score was 17.3% and for the VTE‐BLEED score 9.75%. The performance of the XGBoost algorithm was better than that from the RIETE and VTE‐BLEED scores only in the prospective validation cohort, but not in the external validation cohort.
- 9 June 2021
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 122 (04) , 570-577
Machine Learning to Predict Outcomes in Patients with Acute Pulmonary Embolism Who Prematurely Discontinued Anticoagulant Therapy
Background Patients with pulmonary embolism (PE) who prematurely discontinue anticoagulant therapy (* A full list of the RIETE investigators is given in [ Supplementary Appendix A ] . Received: 03 November 2020 Accepted: 08 June 2021 Accepted Manuscript online: 09 June 2021 Article published online: 13 July 2021 © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 9 June 2021
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 122 (04) , 570-577
Machine Learning to Predict Outcomes in Patients with Acute Pulmonary Embolism Who Prematurely Discontinued Anticoagulant Therapy
Background Patients with pulmonary embolism (PE) who prematurely discontinue anticoagulant therapy (* A full list of the RIETE investigators is given in [ Supplementary Appendix A ] . Received: 03 November 2020 Accepted: 08 June 2021 Accepted Manuscript online: 09 June 2021 Article published online: 13 July 2021 © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 3 June 2020
- Published by Elsevier in Revista Clínica Española
- Vol. 220, 33-40
Profilaxis en cirugía no ortopédica
- 3 June 2020
- Published by Elsevier in Revista Clínica Española
- Vol. 220, 33-40
Profilaxis en cirugía no ortopédica
- 1 May 2020
- Published by Elsevier in Thrombosis Research
- Vol. 189, 61-68
Thirty-day outcomes in patients with proximal deep vein thrombosis who discontinued anticoagulant therapy prematurely
- 1 May 2020
- Published by Elsevier in Thrombosis Research
- Vol. 189, 61-68
Thirty-day outcomes in patients with proximal deep vein thrombosis who discontinued anticoagulant therapy prematurely
- 1 December 2018
- Published by Elsevier in American Heart Journal
- Vol. 206, 1-10
Thirty-day outcomes in patients with acute pulmonary embolism who discontinued anticoagulant therapy before 90 days
- 1 December 2018
- Published by Elsevier in American Heart Journal
- Vol. 206, 1-10
Thirty-day outcomes in patients with acute pulmonary embolism who discontinued anticoagulant therapy before 90 days
- 1 August 2017
- Published by Elsevier in Revista Clínica Española
- Vol. 217 (6) , 365-369
Duración del tratamiento anticoagulante. A favor de plazos cortos
- 1 August 2017
- Published by Elsevier in Revista Clínica Española
- Vol. 217 (6) , 365-369
Duración del tratamiento anticoagulante. A favor de plazos cortos
- 1 October 2015
- Published by Elsevier in Revista Clínica Española
- Vol. 215 (7) , 393-395
Dabigatrán en la vida real
- 1 October 2015
- Published by Elsevier in Revista Clínica Española
- Vol. 215 (7) , 393-395
Dabigatrán en la vida real
- 1 October 2014
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 25 (8) , 717-723
Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients. A retrospective multicenter study
- 1 October 2014
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 25 (8) , 717-723
Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients. A retrospective multicenter study
- Open Access
- 11 July 2013
- Published by Elsevier in Thrombosis Research
- Vol. 132 (2) , 175-179
Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism
- 11 July 2013
- Published by Elsevier in Thrombosis Research
- Vol. 132 (2) , 175-179
Open AccessValidation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism